drugset / Trial / NCT00681668

Quetiapine in Postpartum Depression

NCT00681668

Phase 2 Terminated 5 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms

Timeline

Start
2007-08
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 150 mg Oral
Subject Quetiapine Small molecule 800 mg Oral

Indications